0.08%| Prev Close: | 0.51 |
|---|---|
| Open: | 0.55 |
| Bid: | N/A |
| Ask: | N/A |
| 1y Target Est: | N/A |
| Beta: | -1.31 |
| Next Earnings Date: | N/A |
| Day's Range: | 0.55 - 0.55 |
|---|---|
| 52wk Range: | 0.10 - 4.50 |
| Volume: | 1,000 |
| Avg Vol (3m): | 1,376 |
| Market Cap: | 20.55M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.36 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ARNO THERAPEUTICS, INC FinancialsEDGAR Online Financials(Tue, May 21)
- Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual MeetingPR Newswire(Wed, May 15)
- ARNO THERAPEUTICS, INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- Arno Therapeutics to Collaborate With Clarient for Development of Diagnostic TestGlobeNewswire(Fri, May 10)
- Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to OnapristoneGlobeNewswire(Mon, Apr 8)
- ARNO THERAPEUTICS, INC Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations CounselGlobeNewswire(Tue, Mar 19)
- ARNO THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibiEDGAR Online(Mon, Feb 4)
- Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of DirectorsPR Newswire(Thu, Jan 31)
- ARNO THERAPEUTICS, INC Files SEC form 8-K, Financial Statements and ExhibitsEDGAR Online(Fri, Jan 18)
- ARNO THERAPEUTICS, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Mon, Jan 14)
- ARNO THERAPEUTICS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinancialEDGAR Online(Wed, Dec 19)
- Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical CompoundsBusiness Wire(Wed, Dec 19)
- Arno Therapeutics Reports Findings of New Diagnostic Technique the Potential to Identify Patients with Cancer Who May Respond to Treatment with OnapristoneBusiness Wire(Wed, Dec 5)
- ARNO THERAPEUTICS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinancialEDGAR Online(Tue, Nov 27)
Press Releases
- Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual MeetingPR Newswire(Wed, May 15)
- Arno Therapeutics to Collaborate With Clarient for Development of Diagnostic TestGlobeNewswire(Fri, May 10)
- Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to OnapristoneGlobeNewswire(Mon, Apr 8)
Reports
- No Reports available for ARNI at this time.